PLUS1
9.75
0.21 (2.2%)
0.21 (2.2%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Verrica Parmaceuticals Inc | VRCA | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.78 | 8.9% | 9.54 | 9.00 | 9.9341 | 9.00 | 8.76 | 00:00:05 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 9.53 | 10.36 | 0.83 | 8.01% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 2,763 | 255,094 | $ 9.46 | $ 2,412,934 | 100,133 | 6.40 - 18.67 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:54:17 | 1 | $ 9.75 | USD |
Verrica Parmaceuticals Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 246.27M | 25.81M | 12.32M | $ - | $ - | -1.12 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | 42.90% |
Verrica Parmaceuticals News
| Date | Time | Source | News Article |
|---|---|---|---|
| 6/29/2020 | 16:23 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 6/29/2020 | 16:05 | GlobeNewswire Inc. | Verrica Pharmaceuticals Provides Regulatory Update on VP-102 |
| 6/12/2020 | 17:04 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 6/12/2020 | 16:50 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 6/12/2020 | 16:49 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 6/12/2020 | 10:00 | GlobeNewswire Inc. | Verrica Pharmaceuticals Announces Positive Results from Two.. |
| 6/11/2020 | 17:11 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VRCA Price Data
| Period †| Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 10.60 | 10.6599 | 8.2924 | 9.26 | 130,225 | -1.06 | -10.0% |
| 1 Month | 12.13 | 15.9999 | 8.2924 | 11.62 | 111,158 | -2.59 | -21.35% |
| 3 Months | 10.98 | 15.9999 | 8.2924 | 11.53 | 70,611 | -1.44 | -13.11% |
| 6 Months | 14.60 | 17.60 | 6.40 | 11.87 | 68,626 | -5.06 | -34.66% |
| 1 Year | 11.42 | 18.67 | 6.40 | 12.89 | 65,274 | -1.88 | -16.46% |
| 3 Years | 20.00 | 23.29 | 6.40 | 13.17 | 61,892 | -10.46 | -52.3% |
| 5 Years | 20.00 | 23.29 | 6.40 | 13.17 | 61,892 | -10.46 | -52.3% |
Verrica Parmaceuticals Description
| Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases. Its lead product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a highly contagious and primarily pediatric viral skin disease, and common warts. |
